
Claims

1. A compound having the following structure:



Formula A

or a pharmaceutically acceptable salt or derivative thereof.

2. A pharmaceutical composition comprising a compound according to claim 1, together with one or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of claim 1 or 2, further comprising one or more additional active pharmaceutical ingredients.

4. The pharmaceutical composition of claim 3, wherein the one or more additional active pharmaceutical ingredients is selected from anandamide, oleoyl ethanolamide or palmitoyl ethanolamide.

5. Use of a compound according to claim 1 or a pharmaceutical composition according to any one of claims 2-4 in the manufacture of a medicament for the treatment or prevention of a condition whose development or symptoms are linked to a substrate of the FAAH enzyme, wherein the condition is a disorder associated with the endocannabinoid system; and

wherein the disorder is selected from the appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

6. A process for the synthesis of a compound according to claim 1, in which the process comprises a process for the synthesis of an acid salt of N-methylcyclopentylamine, the process comprising the reaction of cyclopentylamine with a chloroformate or di-*tert*-butyl carbonate, so as to form a cyclopentylcarbamate, followed by reduction of the cyclopentylcarbamate and acidification to the acid salt of N-methylcyclopentylamine.

7. A process for the synthesis of a compound according to claim 1, in which the process comprises a process for the synthesis of an acid salt of N-methylcyclopentylamine, the process comprising the reductive amination of cyclopentanone in the presence of an acid salt of methylamine.